NFE2L2 and cancer: Genetic inactivation of KEAP1, or gain-of-function mutations in the NFE2L2 gene which encodes NRF2, produce highly malignant tumours which can evade the anti-cancer immune response, and are resistant to all existing anti-cancer therapies, including immune checkpoint inhibitors [16].